1
Mucormycosis, the COVID-19 factor and the pressing need for new treatments
Prior to 2021, textbooks about fungal diseases would classify mucormycosis as a very rare infection. However, for the immunosuppressed, mucormycosis…
Browsing: Basic > Immunology
0
Losing control of HIV: KLF2 could trigger impaired T-cell function
‘Controller’ patients naturally suppress HIV infection, but in some patients increased KLF2 expression and impaired T-cell function triggers T cells to abort…
0
Plankton vs parasites
New research using plankton has revealed that not all hosts are equal when it comes to infectious disease spread between…
0
nAbbing SARS-CoV-2 variants
New SARS-CoV-2 variants mean new neutralizing antibodies to deal with them. With the COVID-19 pandemic on its third wave in some…
0
What effect will SARS-CoV-2 variants have on vaccine efficacy?
The ‘inevitable’ domination of novel SARS-CoV-2 variants from Brazil, South Africa and the UK could result in less effective COVID-19…
1
Natural immunity to COVID-19: how long and how strong?
Two recent papers from Public Health England (PHE; London, UK) and Rockefeller University (NY, USA) have shed new light on the duration and quality of protection provided…
0
What are the advantages of the Oxford—AstraZeneca COVID-19 vaccine?
While the latest set of interim vaccine results from Oxford University and AstraZeneca include an efficacy score of 70%, significantly…
0
What is the extent of SARS-CoV-2 immunity post-exposure?
The question of COVID-19 immunity is on everyone’s lips. It is crucial to understand how immunity develops post-exposure to the virus…
0
Cytokine storm could sabotage long-term immunity against SARS-CoV-2
COVID-19 patients who develop a cytokine storm in response to infection could be unable to produce memory cells that provide long-term protection against SARS-CoV-2.
0
Nanobodies engineered from llama antibodies show immunity against SARS-CoV-2
A research team from The Rosalind Franklin Institute, Diamond Light Source, The University of Oxford and Public Health England have engineered nanobodies from llama antibodies that show protective immune effects against SARS-CoV-2.